Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of a third COVID-19 vaccine booster dose in children 12–18 years
TCTR20221215006Phase 3Unknown
- Sponsor
- Chulalongkorn University
- Start
- Dec 2022
- Countries
- 1
01
Overview
Phase 3, single-arm trial in coronavirus disease 2019 (COVID-19), sponsored by Chulalongkorn University. Primary endpoints: Safety of third COVID-19 vaccine booster dose and Immunogenicity of third COVID-19 vaccine booster dose. Status: unknown.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20221215006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221215006.